← Back to Search

Amplification Device

Hearing Aid Amplification for Hearing Loss

N/A

Waitlist Available

Led By Marc Brennan, PhD

Research Sponsored by University of Nebraska Lincoln

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up each test is approximately 30 minutes and will be completed once per subject

Awards & highlights

Study Summary

This trial will test whether using aided measures of spectral resolution can help set the dynamic range of hearing-aid amplification, and whether this results in better speech recognition.

Who is the study for?

This trial is for individuals with hearing loss who have normal eardrum function (tympanograms) and a specific range of hearing thresholds. People with normal hearing can also participate if their hearing level is within the standard limits across various frequencies. Those with cognitive impairments cannot join.Check my eligibility

What is being tested?

The study aims to improve how well people hear different sounds when using a hearing aid by adjusting it based on measures of spectral resolution, which affects speech recognition.See study design

What are the potential side effects?

While not explicitly mentioned, typical side effects from using a hearing aid may include discomfort in the ear, feedback noises, or temporary worsening of auditory perception while getting used to the device.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ each test is approximately 30 minutes and will be completed once per subject

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~each test is approximately 30 minutes and will be completed once per subject

This trial's timeline: 3 weeks for screening, Varies for treatment, and each test is approximately 30 minutes and will be completed once per subject for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Spectral resolution

Speech Recognition

Secondary outcome measures

Working memory

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Hearing AidExperimental Treatment1 Intervention

Group of participants with hearing loss. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels, while manipulating different hearing aid parameters and also without the provision of amplification, will be assessed.

Group II: Normal HearingActive Control1 Intervention

Group of participants with normal hearing that serve as a reference group. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels will be assessed.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Hearing Aid

2006

Completed Phase 1

~190

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institute on Deafness and Other Communication Disorders (NIDCD)NIH

327 Previous Clinical Trials

178,109 Total Patients Enrolled

54 Trials studying Hearing Loss

19,872 Patients Enrolled for Hearing Loss

University of Nebraska LincolnLead Sponsor

34 Previous Clinical Trials

9,810 Total Patients Enrolled

Marc Brennan, PhDPrincipal InvestigatorUniversity of Nebraska Lincoln

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can minors participate in this investigation?

"This medical study is seeking participants aged between 40 and 75 years old."

Answered by AI

Is there a possibility for me to join this research project?

"This trial is searching for 60 patients aged 40 to 75 that are experiencing a hearing impairment. To be eligible, the subject must have normal tympanograms (peak admittance of ≥ 0.2 mmhos in -200 to 50); Hearing thresholds lower than 20 decibels in dB HL from .25 to 8 kHz; Pure-tone average (2, 4 & 6 kHz) hearing loss between 30 and 65dB HL.."

Answered by AI

How many participants are being observed in this medical experiment?

"Affirmative. Information displayed on clinicaltrials.gov reveals that this trial, which was first proposed on April 2nd 2019, is actively searching for candidates to join the study. Sixty patients are required from a single research hub."

Answered by AI

Is this experiment open for enrolment?

"Indeed, according to the information on clinicaltrials.gov, this medical trial is still recruiting participants. It was originally posted on April 2nd 2019 and most recently updated on September 19th 2022. A total of 60 patients must be recruited from a single site for the study to succeed."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Restoration of Spectral Resolution With Hearing-aid Amplification

2019. "Restoration of Spectral Resolution With Hearing-aid Amplification". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03850678.